Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.2605 | 0.5 |
Giardia lamblia | 1,4-alpha-glucan branching enzyme | 0.0366 | 0.2605 | 0.5 |
Trichomonas vaginalis | alpha-amylase, putative | 0.0734 | 0.8545 | 0.8032 |
Brugia malayi | 1,4-alpha-glucan branching enzyme | 0.0366 | 0.2605 | 0.5 |
Trichomonas vaginalis | amylase, putative | 0.0824 | 1 | 1 |
Mycobacterium tuberculosis | 1,4-alpha-glucan branching enzyme GlgB (glycogen branching enzyme) | 0.0366 | 0.2605 | 0.5 |
Chlamydia trachomatis | 1,4-alpha-glucan branching enzyme | 0.0366 | 0.2605 | 0.5 |
Mycobacterium ulcerans | glycogen branching protein | 0.0366 | 0.2605 | 0.5 |
Echinococcus granulosus | glucan 14 alpha branching enzyme 1 | 0.0366 | 0.2605 | 1 |
Echinococcus multilocularis | glucan (1,4 alpha), branching enzyme 1 | 0.0366 | 0.2605 | 1 |
Trichomonas vaginalis | alpha-amylase, putative | 0.0824 | 1 | 1 |
Toxoplasma gondii | glycosyltransferase | 0.0366 | 0.2605 | 0.5 |
Trichomonas vaginalis | alpha-amylase, putative | 0.0824 | 1 | 1 |
Toxoplasma gondii | 1,4-alpha-glucan-branching enzyme | 0.0366 | 0.2605 | 0.5 |
Schistosoma mansoni | starch branching enzyme II | 0.0366 | 0.2605 | 1 |
Trichomonas vaginalis | amylase, putative | 0.0824 | 1 | 1 |
Trichomonas vaginalis | alpha-amylase, putative | 0.0824 | 1 | 1 |
Entamoeba histolytica | alpha-amylase family protein | 0.0824 | 1 | 1 |
Trichomonas vaginalis | alpha-amylase, putative | 0.0824 | 1 | 1 |
Toxoplasma gondii | alpha amylase, catalytic domain-containing protein | 0.0366 | 0.2605 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.082 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.8184 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.